If given the green light by the FDA, a CAR T cell therapy from Kyverna Therapeutics would be the first approved treatment for stiff person syndrome.
This ‘living drug’ could change the course of autoimmune disease
Original Source
This article was collected from: Science News
Gabeshana News automatically collects article information
from external RSS/Atom sources. The original article remains
available at the source website. Please visit the original
source for the complete article and the latest information.